High-rolling investors have positioned themselves bullish on CRISPR Therapeutics CRSP, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CRSP often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for CRISPR Therapeutics. This is not a typical pattern.
The sentiment among these major traders is split, with 77% bullish and 22% bearish. Among all the options we identified, there was one put, amounting to $42,920, and 8 calls, totaling $1,181,820.
Projected Price Targets
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $70.0 and $95.0 for CRISPR Therapeutics, spanning the last three months.
Insights into Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for CRISPR Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CRISPR Therapeutics's whale trades within a strike price range from $70.0 to $95.0 in the last 30 days.
CRISPR Therapeutics Option Volume And Open Interest Over Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| CRSP | CALL | TRADE | BULLISH | 10/18/24 | $70.00 | $845.0K | 9 | 0 |
| CRSP | CALL | SWEEP | BULLISH | 10/18/24 | $80.00 | $121.0K | 154 | 139 |
| CRSP | CALL | SWEEP | BULLISH | 10/18/24 | $75.00 | $49.3K | 8 | 44 |
| CRSP | PUT | SWEEP | BEARISH | 10/18/24 | $72.50 | $42.9K | 1 | 1 |
| CRSP | CALL | TRADE | BEARISH | 10/18/24 | $72.50 | $39.0K | 13 | 25 |
About CRISPR Therapeutics
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
After a thorough review of the options trading surrounding CRISPR Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Present Market Standing of CRISPR Therapeutics
- With a trading volume of 712,013, the price of CRSP is up by 1.32%, reaching $73.9.
- Current RSI values indicate that the stock is may be approaching oversold.
- Next earnings report is scheduled for 46 days from now.
Professional Analyst Ratings for CRISPR Therapeutics
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $83.6.
- An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on CRISPR Therapeutics, which currently sits at a price target of $70.
- Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on CRISPR Therapeutics with a target price of $66.
- Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for CRISPR Therapeutics, targeting a price of $80.
- An analyst from Chardan Capital persists with their Buy rating on CRISPR Therapeutics, maintaining a target price of $112.
- An analyst from Needham has decided to maintain their Buy rating on CRISPR Therapeutics, which currently sits at a price target of $90.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CRISPR Therapeutics options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
